title: Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.
authors.forename: Tom
authors.initials: T
authors.lastname: Powles
authors.forename: Justin
authors.initials: J
authors.lastname: Stebbing
authors.forename: Silvia
authors.initials: S
authors.lastname: Montoto
authors.forename: Mark
authors.initials: M
authors.lastname: Nelson
authors.forename: Brian
authors.initials: B
authors.lastname: Gazzard
authors.forename: Chloe
authors.initials: C
authors.lastname: Orkin
authors.forename: Andy
authors.initials: A
authors.lastname: Webb
authors.forename: Mark
authors.initials: M
authors.lastname: Bower
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005871:Castleman Disease / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006566:Herpesviridae Infections / Q000150:complications / Q000188:drug therapy*; D019288:Herpesvirus 8, Human; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D000069283:Rituximab; D019562:Viral Load
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab